The main aim of proposed work was to develop Pregabalin matrix tablets, sustained release dosage form, for the treatment of epilepsy. Sustained release formulation is the drug delivery system that is designed to achieve a prolonged therapeutic effect by continuously releasing medication over an extended period of time after administration of single dose. The matrix tablets were prepared by direct compression method using Hydroxylpropyl methylcellulose (HPMC K4M, K15M, K100M), Polyvinyl pyrrolidone (PVP K-30) and Microcrystalline cellulose (MCC 101) in varying ratios. Tablets blends were evaluated for loose bulk density, tapped bulk density, compressibility index and angle of repose, shows satisfactory results. The compressed tablets were then evaluated for various physical tests like diameter, thickness, uniformity of weight, hardness, friability, and drug content. The granules exhibited satisfactory rheological demeanor. The results of all these tests were found to be satisfactory. The in vitro dissolution study was carried out for 24 hours using paddle method in phosphate buffer (pH 7.4) as dissolution media. Formulation F1 to F7 failed to sustain release and among all the formulations, F8 shows 77% of drug release at the end of 24 hours. This finding reveals that above a particular concentration of MCC 101, HPMC K-100 and PVP K-30 are capable of providing sustained drug release.